SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBENEWSWIRE) Satsuma Pharmaceuticals, Inc a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine announced randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine.
- Read more about Satsuma Pharmaceuticals Presents Clinical Trials Result for their Migraine Medicine
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/satsuma-pharmaceuticals-presents-clinical-trials-result-for-their-migraine-medicine
No comments:
Post a Comment